Tempest Therapeutics Terminates ATM Prospectus Supplement

Summary

Tempest Therapeutics Inc. announced the suspension and termination of its ATM prospectus supplement filed on February 6, 2025, concerning the issuance of company common stock under an agreement with Jefferies LLC. This decision was communicated on June 11, 2025, halting any sales of securities under this agreement until a new prospectus or registration statement is filed. Reuters

Impact Analysis

The event is classified at the company level, as it specifically concerns Tempest Therapeutics’ decision to terminate its ATM offering prospectus. The direct impact (first-order effect) is on Tempest’s ability to raise capital through stock sales in the near term, which might affect its liquidity and capital planning strategies. The immediate market reaction could involve shifts in investor sentiment due to uncertainties regarding the company’s funding strategies. Second-order effects might include potential impacts on partners and suppliers if the company faces funding constraints, or a need for alternative financing mechanisms. Investment opportunities or risks involve closely monitoring Tempest’s financial strategy adjustments and assessing the company’s stock volatility in response to this announcement. Reuters+ 2